About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Chapters
Books
News
Editorials
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Scientometrics
Impact Factor
Discipline Ranks
H-Index
G-Index
Articles
Citations
Article Citations
Citation Distribution
Search This Journal
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
exaly
›
Journals
›
Journal of Clinical Pharmacology
›
Top Articles
Journal of Clinical Pharmacology
Pharmacology
2.9
(top 6%)
Impact Factor
3.1
(top 6%)
extended IF
116
(top 3%)
H-Index
1.8K
authors
7.3K
papers
150.1K
citations
7K
citing journals
54.1K
citing authors
Most Cited Articles of Journal of Clinical Pharmacology
Title
Year
Citations
Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use
2005
973
A classification of antiarrhythmic actions reassessed after a decade of new drugs
1984
601
Pharmacokinetics and bioavailability of quercetin glycosides in humans
2001
423
A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals
2002
392
The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity
2006
385
Global burden of disease (GBD) for hepatitis C
2004
375
DHEA and DHEA-S: a review
1999
370
Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis
2005
350
Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)
2010
337
Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers
2010
337
Cannabidiol: an overview of some pharmacological aspects
2002
306
Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans
2010
296
Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases
2002
292
Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs
2007
283
Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma
1996
280
New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process
2008
273
Nuclear factor kappa B: important transcription factor and therapeutic target
1998
272
Stability and performance of a population pharmacokinetic model
1997
261
Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial
2000
261
Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration
1996
253
Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis
1995
235
Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches
2009
233
Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects
2007
231
Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study
1993
229
Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans
1997
228
previous
2008
2009
2010
How are inpact factors calculated?
The impact factor (IF) is calculated by counting citations from peer-reviewed journals only.
extended IF
also counts citations from books and conference papers. However, no patent, abstract, working papers, online documents, etc., are covered.
site/software ©
exaly
; All materials licenced under
CC by-SA
.